Sue Zann Lim1, Cedric Chuan Young Ng2,3, Vikneswari Rajasegaran2,3, Peiyong Guan4, Sathiyamoorthy Selvarajan5, Aye Aye Thike5, Nur Diyana Binte Md Nasir5, Valerie Cui Yun Koh5, Benita Kiat Tee Tan1, Kong Wee Ong1, Bin Tean Teh2,3,6,7, Puay Hoon Tan8. 1. SingHealth Duke-National University of Singapore Breast Centre, Singapore, Singapore. 2. Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore. 3. Division of Cancer and Stem Cell Biology, Duke-National University of Singapore Medical School, Singapore, Singapore. 4. Integrated Biostatistics and Bioinformatics Programme, Duke-National University of Singapore Medical School, Singapore, Singapore. 5. Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore. 6. Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. 7. Institute of Molecular and Cellular Biology, Singapore, Singapore. 8. Division of Pathology, Singapore General Hospital, Level 7, Diagnostics Tower, Academia, 20 College Road, Singapore, 169856, Singapore. tan.puay.hoon@singhealth.com.sg.
Abstract
PURPOSE: We aimed to investigate the genomic profile of breast sarcomas (BS) and compare with that of malignant phyllodes tumours (MPT). METHODS: DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) specimens from 17 cases of BS diagnosed at Singapore General Hospital from January 1991 to December 2014. Targeted deep sequencing and copy number variation (CNV) analysis on 16 genes, which included recurrently mutated genes in phyllodes tumours and genes associated with breast cancer, were performed on these samples. Genetic alterations (GA) observed were summarised and analysed. RESULTS: Nine cases met the quality control requirements for both targeted deep sequencing and CNV analysis. Three (33.33%) were angiosarcomas and 6 (66.67%) were non-angiosarcomas. In the non-angiosarcoma group, 83.33% (n = 5) of the patients had GA in the TERT gene. The other commonly mutated genes in this group of tumours were MED12 (n = 4, 66.67%), BCOR (n = 4, 66.67%), KMT2D (n = 3, 50%), FLNA (n = 3, 50%) and NF1 (n = 3, 50%). In contrast, none of the angiosarcomas had mutations or copy number alterations in TERT, MED12, BCOR, FLNA or NF1. Eighty percent of patients with GA in TERT (n = 5) had concurrent mutations in MED12. Sixty percent (n = 3) of these cases also demonstrated GA in NF1, PIK3CA or EGFR which are known cancer driver genes. CONCLUSIONS: The non-angiosarcoma group of BS was found to share similar GA as those described for MPT, which may suggest a common origin and support their consideration as a similar group of tumours with regard to management and prognostication.
PURPOSE: We aimed to investigate the genomic profile of breast sarcomas (BS) and compare with that of malignant phyllodes tumours (MPT). METHODS: DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) specimens from 17 cases of BS diagnosed at Singapore General Hospital from January 1991 to December 2014. Targeted deep sequencing and copy number variation (CNV) analysis on 16 genes, which included recurrently mutated genes in phyllodes tumours and genes associated with breast cancer, were performed on these samples. Genetic alterations (GA) observed were summarised and analysed. RESULTS: Nine cases met the quality control requirements for both targeted deep sequencing and CNV analysis. Three (33.33%) were angiosarcomas and 6 (66.67%) were non-angiosarcomas. In the non-angiosarcoma group, 83.33% (n = 5) of the patients had GA in the TERT gene. The other commonly mutated genes in this group of tumours were MED12 (n = 4, 66.67%), BCOR (n = 4, 66.67%), KMT2D (n = 3, 50%), FLNA (n = 3, 50%) and NF1 (n = 3, 50%). In contrast, none of the angiosarcomas had mutations or copy number alterations in TERT, MED12, BCOR, FLNA or NF1. Eighty percent of patients with GA in TERT (n = 5) had concurrent mutations in MED12. Sixty percent (n = 3) of these cases also demonstrated GA in NF1, PIK3CA or EGFR which are known cancer driver genes. CONCLUSIONS: The non-angiosarcoma group of BS was found to share similar GA as those described for MPT, which may suggest a common origin and support their consideration as a similar group of tumours with regard to management and prognostication.
Entities:
Keywords:
Genomic profile; MED 12; Mesenchymal; NF1; TERT
Authors: Lily Gutnik; Yi Ren; Samantha M Thomas; Jennifer K Plichta; Rachel A Greenup; Oluwadamilola M Fayanju; E Shelley Hwang; Laura H Rosenberger Journal: J Surg Oncol Date: 2022-02-18 Impact factor: 3.454
Authors: Francisco Beca; Gregor Krings; Yunn-Yi Chen; Elizabeth M Hosfield; Poonam Vohra; Richard K Sibley; Megan L Troxell; Robert B West; Kimberly H Allison; Gregory R Bean Journal: Mod Pathol Date: 2020-03-02 Impact factor: 7.842
Authors: Fredrik Karlsson; Fredrik Granath; Karin E Smedby; Jan Zedenius; Robert Bränström; Inga-Lena Nilsson Journal: Breast Cancer Res Treat Date: 2020-07-21 Impact factor: 4.872